- £73.57bn
- £86.64bn
- £30.33bn
- 87
- 44
- 98
- 91
REG - GSK PLC - ViiV LAI superior to orals in adherence-challenged
AnnouncementREG - GSK PLC - Julie Brown - External Appointment
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK completes acquisition of Aiolos Bio
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - US FDA Fast Track designation for bepirovirsen
AnnouncementREG - GSK PLC - Shingrix 18+ at risk China filing review accepted
AnnouncementREG - GSK PLC - FDA accepts Arexvy filing for adults 50-59 at risk
AnnouncementREG - GSK PLC - GSK presents positive DREAMM-7 phase III data
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
Announcement